Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Braz. j. infect. dis ; 21(1): 1-6, Jan.-Feb. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-839191

RESUMEN

Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Carbapenémicos/uso terapéutico , Farmacorresistencia Bacteriana , Infecciones por Enterobacteriaceae/mortalidad , Neumonía Asociada al Ventilador/mortalidad , Antibacterianos/uso terapéutico , Factores de Tiempo , Modelos Logísticos , Estudios Transversales , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Mortalidad Hospitalaria , Estadísticas no Paramétricas , Enterobacter aerogenes/efectos de los fármacos , Quimioterapia Combinada/mortalidad , Neumonía Asociada al Ventilador/microbiología , Neumonía Asociada al Ventilador/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos
2.
Braz. j. infect. dis ; 18(4): 360-363, Jul-Aug/2014. tab
Artículo en Inglés | LILACS | ID: lil-719295

RESUMEN

BACKGROUND: Local epidemiological data are always helpful when choosing the best antibiotic regimen, but it is more complex than it seems as it may require the analysis of multiple combinations. The aim of this study was to demonstrate a simplified mathematical calculation to determine the most appropriate antibiotic combination in a scenario where monotherapy is doomed to failure. METHODS: The susceptibility pattern of 11 antibiotics from 216 positive blood cultures from January 2012 to January 2013 was analyzed based on local policy. The length of hospitalization before bacteremia and the unit (ward or intensive care unit) were the analyzed variables. Bacteremia was classified as early, intermediate or late. The antibiotics were combined according to the combination model presented herein. RESULTS: A total of 55 possible mathematical associations were found combining 2 by 2, 165 associations with 3 by 3 and 330 combinations with 4 by 4. In the intensive care unit, monotherapy never reached 80% of susceptibility. In the ward, only carbapenems covered more than 90% of early bacteremia. Only three drugs combined reached a susceptibility rate higher than 90% anywhere in the hospital. Several regimens using four drugs combined reached 100% of susceptibility. CONCLUSIONS: Association of three drugs is necessary for adequate coverage of empirical treatment of bacteremia in both the intensive care unit and the ward. .


Asunto(s)
Humanos , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Modelos Biológicos , Estudios Transversales , Unidades de Cuidados Intensivos
3.
Braz. j. infect. dis ; 16(5): 416-419, Sept.-Oct. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-653427

RESUMEN

The molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae (KPC) has been largely investigated, but limited clinical information is available. A case-control study was performed to evaluate the risk factors for KPC bacteremia in hospitalized patients. Cases were patients with KPC bacteremia and controls were patients with non-KPC bacteremia. A total of 85 patients were included, 18 (21.2%) were KPC, and 67 (78.8%) were non-KPC (40 [59.7%] of them were extended-spectrum beta-lactamase producers). All KPC isolates were type 2 producers. These isolates belong to five distinct clones. Multivariate analysis showed that age (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02 - 1.11; p = 0.004), presence of mechanical ventilation (OR, 11.1; 95% CI, 1.92 - 63.3; p = 0.007) and fluoroquinolone exposure during hospitalization (OR, 28.9; 95% CI, 1.85 - 454.6; p = 0.02) were independent risk factors for KPC in patients with K. pneumoniae bacteremia. Factors associated with severity of illness, such as age and mechanical ventilation, seem to be the main risks factors for KPC. Fluoroquinolones use might be a risk factor for KPC bacteremia. Further investigations on risk factors for KPC are warranted.


Asunto(s)
Femenino , Humanos , Masculino , Persona de Mediana Edad , Bacteriemia/microbiología , Proteínas Bacterianas/metabolismo , Infección Hospitalaria/microbiología , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , beta-Lactamasas/metabolismo , Bacteriemia/diagnóstico , Infección Hospitalaria/diagnóstico , Métodos Epidemiológicos , Infecciones por Klebsiella/diagnóstico , Infecciones por Klebsiella/epidemiología
4.
Braz. j. infect. dis ; 16(4): 351-356, July-Aug. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-645424

RESUMEN

INTRODUCTION: The aim of this study was to determine risk factors for acquiring carbapenemresistant Pseudomonas aeruginosa bacteremia (CR-PA) and factors associated with in-hospital mortality. METHODS: Seventy-seven cases of bacteremia caused by P. aeruginosa were evaluated in a hospital with high incidence of CR-PA. Clinical and laboratorial factors, and previous use of antibiotics were also evaluated. In one analysis, CR-PA and carbapenem-susceptible P. aeruginosa (CS-PA) bacteremia were compared. A second analysis compared patients who died with survivors. RESULTS: Among 77 P. aeruginosa bacteremia, 29 were caused by CR-PA. Admission to the intensive care unit, higher number of total leukocytes, and previous use of carbapenem were statistically associated with CR-PA. In the multivariate analysis, only previous use of carbapenem (including ertapenem) turned out to be a risk factor for CR-PA (p = 0.014). The 30-day mortality of patients with P. aeruginosa bloodstream infection was 44.8% for CS-PA and 54.2% for patients with CR-PA (p = 0.288). Chronic renal failure, admission to the intensive care unit, mechanical ventilation, and central venous catheter were risk factors for mortality. Incorrect treatment increased mortality of patients with bacteremia caused by CS-PA, but not for CR-SA. The odd ratio of mortality associated with incorrect therapy in patients with CS-PA was 3.30 (1.01-10.82; p = 0.043). The mortality of patients with bacteremia caused by CR-PA was unexpectedly similar regardless of antimicrobial treatment adequacy. CONCLUSION: Appropriate treatment for CS-PA bacteremia initiated within the first 24 hours was associated with lower mortality, but this cannot be extrapolated for CR-PA.


Asunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antibacterianos/administración & dosificación , Resistencia betalactámica , Bacteriemia/tratamiento farmacológico , Carbapenémicos/administración & dosificación , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Bacteriemia/microbiología , Bacteriemia/mortalidad , Estudios de Casos y Controles , Mortalidad Hospitalaria , Infecciones por Pseudomonas/microbiología , Infecciones por Pseudomonas/mortalidad , Factores de Riesgo
5.
Braz. j. infect. dis ; 16(2): 115-121, May-Apr. 2012. tab
Artículo en Inglés | LILACS | ID: lil-622730

RESUMEN

BACKGROUND: Optimal empirical therapy of urinary tract infection requires accurate knowledge of local susceptibility patterns, which may vary with organism and patient characteristics. METHODS: Among 9,798 consecutive, non-duplicate, community-source urine isolates from ambulatory patients > 13 years old, from clinical laboratory and an academic medical center in Curitiba, Brazil (May 1st to December 1st, 2009), susceptibility data for ampicillin, nitrofurantoin, trimethoprim-sulfamethoxazole, gentamicin, fluoroquinolones, and ceftriaxone/cefotaxime were compared with organism and patient gender and age. RESULTS: The female-to-male ratio decreased with age, from 28.1 (among 20-29 year-olds) to 3.3 (among > 80 year-olds). Overall, susceptibility prevalence varied widely by drug class, from unacceptably low levels (53.5% and 61.1%: ampicillin and trimethoprimsulfamethoxazole) to acceptable but suboptimal levels (81.2% to 91.7%: fluoroquinolones, ceftriaxone, nitrofurantoin, and gentamicin). E. coli isolates exhibited higher susceptibility rates than other isolates, from 3-4% higher (fluoroquinolones, gentamicin) to > 30% (nitrofurantoin, ceftriaxone). Males exhibited lower susceptibility rates than females. Within each gender, susceptibility declined with increasing age. For females, only nitrofurantoin and gentamicin were suitable for empirical therapy (> 80% susceptibility) across all age cohorts; fluoroquinolones were suitable only through age 60, and ceftriaxone only through age 80. For males, only gentamicin yielded > 80% susceptibility in any age cohort. CONCLUSION: Few suitable empirical treatment options for community-source urinary tract infection were identified for women aged over 60 years or males of any age. Empirical therapy recommendations must consider the patient's demographic characteristics. Site-specific, age and gender-stratified susceptibility surveillance involving all uropathogens is needed.


Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Antibacterianos/farmacología , Farmacorresistencia Bacteriana/efectos de los fármacos , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Infecciones Urinarias/microbiología , Factores de Edad , Brasil/epidemiología , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Bacterias Gramnegativas/aislamiento & purificación , Bacterias Grampositivas/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Factores Sexuales , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/epidemiología
7.
Arq. bras. endocrinol. metab ; 46(3): 221-229, jun. 2002. tab
Artículo en Portugués | LILACS | ID: lil-313126

RESUMEN

O diabetes mellitus (DM) é uma doença de alta prevalência nas sociedades modernas, na maioria das vezes com tratamento inadequado ou ausente. Apesar de geralmente considerado como fator de risco independente para ocorrência e gravidade de infecções em geral, o DM não apresenta evidência clínica forte de sua relação com infecção. Observa-se, porém, uma maior ocorrência de certas infecções em pacientes com DM, com curso menos favorável para algumas delas. Há também tipos de infecção quase exclusivos de pacientes com DM. Experimentalmente, observa-se depressão da atividade dos neutrófilos, menor eficiência da imunidade celular, alteração dos sistemas antìoxidantes e menor produção de interleucinas. Com relação às infecções comuns, as que envolvem o trato respiratório não têm comprovadamente maior gravidade em pacientes com DM, exceção feita ao pneumococo - por isso a recomendação para sua vacinação contra S. pneumoniae e influenza. Quanto ao trato urinário, há maior ocorrência de bacteriúria assintomática em mulheres com DM, com maiores índices de pielonefrite, necrose papilar, abscesso perinéfrico, pìelonefrite xantogranulomatosa, e cistite e pielonefrite gangrenosas. Periodontite e infecções de partes moles são também mais comuns no DM. Cada tipo de infecção é associado a germes típicos, e seu conhecimento é fundamental para um tratamento inicial adequado. As infecções quase exclusivas de pacientes com DM incluem otite externa maligna, mucormicose rinocerebral, colecistìte gangrenosa e o somatório de alterações que caracterizam o pé diabético. O conhecimento destas infecções assume maior importância por requererem freqüentemente uma abordagem multidisciplinar, envolvendo endocrinologistas, infectologistas, cirurgiões vasculares e nefrologistas, dentre outros.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Diabetes Mellitus , Infecciones/inmunología , Antibacterianos/uso terapéutico , Pie Diabético , Infecciones/tratamiento farmacológico , Infecciones del Sistema Respiratorio , Infecciones de los Tejidos Blandos , Infecciones Urinarias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA